Skip to content
IVOIVOIVO250250250

Drawing based on the label description. No photo yet.

“Tablets: 250 mg as a blue oval-shaped film-coated tablet debossed "IVO" on one side and "250" on the other side”

IVO 250 pill

Pill with imprint IVO 250 is blue, oval, 18 mm and has been identified as Ivosidenib 250 mg. It is used for acute myeloid leukemia. It is supplied by Servier Pharmaceutical LLC.

Ivosidenib 250 mg

Imprint
IVO 250
Strength
250 mg
Used for
Acute myeloid leukemia
Color
Blue
Shape
Oval
Size
18 mm
Score
No score line
Form
Tablet, film coated
Manufacturer
Servier Pharmaceutical LLC
Drug class
Isocitrate dehydrogenase 1 inhibitor
NDC
72694-617, 72694-617-60

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Ivosidenib pills and guides

What is Ivosidenib used for?

Ivosidenib is used for acute myeloid leukemia.

Medicine type
Isocitrate dehydrogenase 1 inhibitor
Official uses from the US prescribing label

Newly Diagnosed Acute Myeloid Leukemia

TIBSOVO is indicated in combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Relapsed or Refractory Acute Myeloid Leukemia

TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Relapsed or Refractory Myelodysplastic Syndromes

TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

Locally Advanced or Metastatic Cholangiocarcinoma

TIBSOVO is indicated for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

From the FDA-approved label on DailyMed (published Dec 22, 2025).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows IVO and the other side shows 250.
  • It is blue, oval, 18 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold under the brand name Tibsovo.

Ingredients

Active: Ivosidenib

Inactive: Silicon Dioxide, Croscarmellose Sodium, Hypromellose Acetate Succinate 06081224 (3 Mpa.s), Magnesium Stearate, Microcrystalline Cellulose, Sodium Lauryl Sulfate, Fd&c Blue No. 2, Hypromellose, Unspecified, Lactose Monohydrate, Titanium Dioxide, Triacetin

Other pills with imprint IVO 250

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.